

Fycompa Approval Status Worldwide (Country/ Region)

July, 2022

Partial-onset seizures

Argentina	Apr-2019	Germany	Jul-2012	Malta	Jul-2012	South Africa	Feb-2017
Australia	May-2014	Greece	Jul-2012	Mexico	Nov-2014	South Korea	Jul-2015
Austria	Jul-2012	Hong Kong	Apr-2014	Myanmar	Jun-2016	Spain	Jul-2012
Bahrain	Nov-2017	Hungary	Jul-2012	Namibia	Dec-2020	Sweden	Jul-2012
Belgium	Jul-2012	Iceland	Sep-2012	Netherlands	Jul-2012	Switzerland	Dec-2012
Brazil	May-2016	India	Feb-2016	New Zealand	Sep-2020	Taiwan	Aug-2014
Brunei	Jul-2019	Indonesia	Sep-2019	Norway	Aug-2012	Thailand	Dec-2014
Bulgaria	Jul-2012	Ireland	Jul-2012	Oman	Jun-2017	UAE	Dec-2013
Cambodia	Aug-2017	Israel	Aug-2013	Pakistan	Jan-2019	UK	Jul-2012
Canada	Apr-2013	Italy	Jul-2012	Peru	Aug-2020	US	Oct-2012
Chile	Nov-2019	Japan	Mar-2016	Philippines	Mar-2015	Vietnam	Mar-2019
China	Sep-2019	Jordan	Jul-2016	Poland	Jul-2012	Zambia	Nov-2019
Croatia	Jul-2013	Kuwait	Apr-2015	Portugal	Jul-2012	Zimbabwe	Mar-2020
Cyprus	Jul-2012	Latvia	Jul-2012	Qatar	Apr-2019		
Czech Republic	Jul-2012	Lebanon	Dec-2015	Romania	Jul-2012		
Denmark	Jul-2012	Liechtenstein	Jul-2012	Russia	Aug-2013		
Ecuador	Oct-2020	Lithuania	Jul-2012	Saudi Arabia	Jul-2017		
Estonia	Jul-2012	Luxembourg	Jul-2012	Singapore	Sep-2014		
Finland	Jul-2012	Macau	Nov-2014	Slovakia	Jul-2012		
France	Jul-2012	Malaysia	Mar-2014	Slovenia	Jul-2012		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Fycompa Approval Status Worldwide (Country/ Region)

July, 2022

Primary generalized tonic-clonic (PGTC) seizures

Argentina	Apr-2019	Greece	Jun-2015	Myanmar	Jul-2019	Spain	Jun-2015
Australia	May-2016	Hong Kong	Apr-2016	Namibia	Dec-2020	Switzerland	Mar-2016
Austria	Jun-2015	Hungary	Jun-2015	Netherlands	Jun-2015	Sweden	Jun-2015
Bahrain	Nov-2017	Iceland	Jun-2015	New Zealand	Sep-2020	Taiwan	May-2016
Belgium	Jun-2015	India	Sep-2019	Norway	Jun-2015	Thailand	Sep-2017
Brazil	Jul-2019	Indonesia	Jul-2020	Oman	Jun-2017	UAE	Dec-2013
Brunei	Jul-2019	Ireland	Jun-2015	Pakistan	Jan-2019	UK	Jun-2015
Bulgaria	Jun-2015	Israel	Nov-2015	Peru	Aug-2020	US	Jun-2015
Cambodia	Mar-2020	Italy	Jun-2015	Philippines	Nov-2015	Vietnam	Mar-2019
Canada	Dec-2015	Japan	Mar-2016	Poland	Jun-2015	Zambia	Nov-2019
Chile	Nov-2019	Jordan	Oct-2018	Portugal	Jun-2015	Zimbabwe	Mar-2020
Croatia	Jun-2015	Kuwait	Mar-2017	Qatar	Apr-2019		
Cyprus	Jun-2015	Latvia	Jun-2015	Romania	Jun-2015		
Czech Republic	Jun-2015	Lebanon	Jul-2016	Russia	Jun-2015		
Denmark	Jun-2015	Liechtenstein	Jun-2015	Saudi Arabia	Aug-2020		
Ecuador	Oct-2020	Lithuania	Jun-2015	Singapore	Nov-2016		
Estonia	Jun-2015	Luxembourg	Jun-2015	Slovakia	Jun-2015		
Finland	Jun-2015	Macau	Nov-2016	Slovenia	Jun-2015		
France	Jun-2015	Malaysia	Mar-2017	South Africa	Dec-2019		
Germany	Jun-2015	Malta	Jun-2015	South Korea	Jul-2016		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.